Claritas (formerly Kalytera Therapeutics, Inc.) Announces Addition of Professor Salvatore Cuzzocrea, Ph.D. to the Company’s Board of Directors

    NEXT STORY
    Predictmedix Inc. Secures Strategic Financing to Catalyze Operations
    PREV STORY
    Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical’s Razuprotafib in I-SPY COVID Trial
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    AXIM® Biotechnologies Completes Acquisition of Oncology Research and Development Company Sapphire Biotech, Inc.

    author_avatar
    NASDAQ Market News

    Medtronic Enrolls First Patient in Clinical Study to Assess Pain Control and Oral Opioid Elimination with Targeted Drug Delivery

    Study Will Further Advance Understanding of Effectiveness and Tolerability of the SynchroMed(TM) II Intrathecal ...

    author_avatar
    NASDAQ Market News

    FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer

    author_avatar
    NASDAQ Market News